New predictors for immunotherapy responses sharpen our view of the tumour microenvironment.
Where this comes from
- Record sourced from PubMed, PMID 31965091.
- Also identified by DOI 10.1038/d41586-019-03943-0 and PMC identifier PMC2866639.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Three studies reveal that the presence in tumours of two key immune components — B cells and tertiary lymphoid structures — is associated with favourable outcomes when individuals undergo immunotherapy.